| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Annals of Surgical Oncology, Vol 6, Issue 8 727-731, Copyright © 1999 by Society of Surgical Oncology
ARTICLES |
P. H. Sugarbaker and D. Chang
Washington Cancer Institute, Washington, DC 20010, USA.
INTRODUCTION: In the past, peritoneal carcinomatosis, regardless of primary tumor type, has always been a lethal condition. Recently, special treatments using cytoreductive surgery with peritonectomy procedures combined with perioperative intraperitoneal chemotherapy have resulted in long-term survival. Appendiceal malignancy with a low incidence of liver and lymph node metastases may be especially appropriate for these aggressive local regional treatments. METHODS: All patients treated with surgery before January 1999 are included. Patients left with gross residual disease after surgery were not given intraperitoneal chemotherapy, but were later treated with intravenous chemotherapy. The intraperitoneal chemotherapy was given in the perioperative period, starting with mitomycin C at 12.5 mg/m2 for males and 10 mg/m2 for females. For patients whose pathology showed adenomucinosis, intraperitoneal chemotherapy was limited to treatment in the operating theater with heated mitomycin C. Patients with mucinous adenocarcinoma or pseudomyxoma/adenocarcinoma hybrid had, in addition to mitomycin C, five consecutive days of intraperitoneal 5-fluorouracil at 650 mg/m2 instilled in 1-1.5 liters of 1.5% dextrose peritoneal dialysis solution. A complete cytoreduction was defined as tumor nodules <2.5 mm in diameter remaining after surgery. The histopathology categorized the patients as having adenomucinosis, adenomucinosis/carcinomatosis hybrid, or mucinous carcinomatosis. A previous surgical score was used to estimate the extent of previous surgical procedures. RESULTS: The morbidity of treated patients was 27% and the mortality was 2.7%. In a multivariate analysis, prognostic factors for survival included the completeness of cytoreduction (P < .0001), the histopathological character of the appendix malignancy (P < .0001), and the extent of previous surgical interventions (P = .001). Patients with a complete cytoreduction and adenomucinosis by pathology had a 5-year survival of 86%; with hybrid pathology, survival at 5 years was 50%. Incomplete cytoreduction had a 5-year survival of 20% and 0% at 10 years. CONCLUSIONS: Cytoreductive surgery and perioperative intraperitoneal chemotherapy can be used to salvage selected patients with peritoneal surface spread of appendiceal primary tumors. Similar strategies for other patients with peritoneal surface malignancy such as peritoneal carcinomatosis from colon or gastric cancer, peritoneal sarcomatosis, or peritoneal mesothelioma should be pursued.
This article has been cited by other articles:
 |
|
 |
|
  L. E. Harrison, M. Bryan, L. Pliner, and T. Saunders Phase I Trial of Pegylated Liposomal Doxorubicin with Hyperthermic Intraperitoneal Chemotherapy in Patients Undergoing Cytoreduction for Advanced Intra-abdominal Malignancy Ann. Surg. Oncol., May 1, 2008; 15(5): 1407 - 1413. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Logan-Collins, A. M. Lowy, T. M. Robinson-Smith, S. Kumar, J. J. Sussman, L. E. James, and S. A. Ahmad VEGF Expression Predicts Survival in Patients with Peritoneal Surface Metastases from Mucinous Adenocarcinoma of the Appendix and Colon Ann. Surg. Oncol., March 1, 2008; 15(3): 738 - 744. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. N. Low, R. M. Barone, J. M. Gurney, and W. D. Muller Mucinous Appendiceal Neoplasms: Preoperative MR Staging and Classification Compared with Surgical and Histopathologic Findings Am. J. Roentgenol., March 1, 2008; 190(3): 656 - 665. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Baratti, S. Kusamura, D. Nonaka, M. Langer, S. Andreola, M. Favaro, C. Gavazzi, B. Laterza, and M. Deraco Pseudomyxoma Peritonei: Clinical Pathological and Biological Prognostic Factors in Patients Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Ann. Surg. Oncol., February 1, 2008; 15(2): 526 - 534. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. P. McQuellon, G. B. Russell, P. Shen, J. H. Stewart IV, W. Saunders, and E. A. Levine Survival and Health Outcomes After Cytoreductive Surgery With Intraperitoneal Hyperthermic Chemotherapy for Disseminated Peritoneal Cancer of Appendiceal Origin Ann. Surg. Oncol., January 1, 2008; 15(1): 125 - 133. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. A. Levine, B. M. Ronnett, P. F. Mansfield, and C. Eng Overview of Cytoreductive Surgery and Intraperitoneal Hyperthermic Chemotherapy for Peritoneal Dissemination of Appendiceal and Colorectal Neoplasms ASCO Educational Book, January 1, 2008; 2008(1): 153 - 159. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. A. Lambert and P. F. Mansfield Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy for Colorectal Carcinomatosis: If at First You Don't Succeed... Ann. Surg. Oncol., November 1, 2007; 14(11): 3037 - 3039. [Full Text] [PDF]
|
|
|
|
|
|
D. Baratti, S. Kusamura, D. Nonaka, G. D. Oliva, B. Laterza, and M. Deraco Multicystic and Well-differentiated Papillary Peritoneal Mesothelioma Treated by Surgical Cytoreduction and Hyperthermic Intra-peritoneal Chemotherapy (HIPEC) Ann. Surg. Oncol., October 1, 2007; 14(10): 2790 - 2797. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Baratti, S. Kusamura, A. Martinetti, E. Seregni, B. Laterza, D. G. Oliva, and M. Deraco Prognostic Value of Circulating Tumor Markers in Patients with Pseudomyxoma Peritonei Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Ann. Surg. Oncol., August 1, 2007; 14(8): 2300 - 2308. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. A. Khan, J. Tambiah, P. Cane, and L. Lang-Lazdunski Prolonged Survival in a Patient With Recurrent Pulmonary Metastases Secondary to Mucinous Cystadenocarcinoma of the Appendix With Pseudomyxomatous Peritonei Ann. Thorac. Surg., May 1, 2007; 83(5): 1893 - 1894. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. D. Yan, D. Black, R. Savady, and P. H. Sugarbaker A Systematic Review on the Efficacy of Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy for Pseudomyxoma Peritonei Ann. Surg. Oncol., February 1, 2007; 14(2): 484 - 492. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Maheshwari, A. Tsung, Y. Lin, H. J. Zeh III, S. D. Finkelstein, and D. L. Bartlett Analysis of Loss of Heterozygosity for Tumor-Suppressor Genes Can Accurately Classify and Predict the Clinical Behavior of Mucinous Tumors Arising From the Appendix Ann. Surg. Oncol., December 1, 2006; 13(12): 1610 - 1616. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. M. Tuttle, Y. Zhang, E. Greeno, and A. Knutsen Toxicity and Quality of Life after Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy Ann. Surg. Oncol., December 1, 2006; 13(12): 1627 - 1632. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. H. Stewart IV, P. Shen, G. B. Russell, R. F. Bradley, J. C. Hundley, B. L. Loggie, K. R. Geisinger, and E. A. Levine Appendiceal Neoplasms With Peritoneal Dissemination: Outcomes After Cytoreductive Surgery and Intraperitoneal Hyperthermic Chemotherapy Ann. Surg. Oncol., May 1, 2006; 13(5): 624 - 634. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. H. Sugarbaker, R. Alderman, G. Edwards, C. E. Marquardt, V. Gushchin, J. Esquivel, and D. Chang Prospective Morbidity and Mortality Assessment of Cytoreductive Surgery Plus Perioperative Intraperitoneal Chemotherapy To Treat Peritoneal Dissemination of Appendiceal Mucinous Malignancy Ann. Surg. Oncol., May 1, 2006; 13(5): 635 - 644. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Brigand, O. Monneuse, F. Mohamed, A. C. Sayag-Beaujard, S. Isaac, F. N. Gilly, and O. Glehen Peritoneal Mesothelioma Treated by Cytoreductive Surgery and Intraperitoneal Hyperthermic Chemotherapy: Results of a Prospective Study Ann. Surg. Oncol., March 1, 2006; 13(3): 405 - 412. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. H. Sugarbaker Decreasing the Risk of a Treatment Expands Its Indications Ann. Surg. Oncol., November 1, 2005; 12(11): 868 - 870. [Full Text] [PDF]
|
|
|
|
|
|
J. H. Stewart IV, P. Shen, and E. A. Levine Intraperitoneal Hyperthermic Chemotherapy for Peritoneal Surface Malignancy: Current Status and Future Directions Ann. Surg. Oncol., October 1, 2005; 12(10): 765 - 777. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. J. Verwaal, S. van Ruth, A. Witkamp, H. Boot, G. van Slooten, and F. A. N. Zoetmulder Long-Term Survival of Peritoneal Carcinomatosis of Colorectal Origin Ann. Surg. Oncol., January 1, 2005; 12(1): 65 - 71. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Gonzalez-Moreno, E. Brun, and P. H. Sugarbaker Lymph Node Metastasis in Epithelial Malignancies of the Appendix With Peritoneal Dissemination Does Not Reduce Survival in Patients Treated by Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy Ann. Surg. Oncol., January 1, 2005; 12(1): 72 - 80. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. S. Levitz, P. H. Sugarbaker, S. M. Lichtman, and E. A. Brun Unusual Abdominal Tumors: CASE 1. Pseudomyxoma Peritonei: Response to Capecitabine J. Clin. Oncol., April 15, 2004; 22(8): 1518 - 1520. [Full Text] [PDF]
|
|
|
|
|
|
S. A. Ahmad, J. Kim, J. J. Sussman, D. A. Soldano, L. J. Pennington, L. E. James, and A. M. Lowy Reduced Morbidity Following Cytoreductive Surgery and Intraperitoneal Hyperthermic Chemoperfusion Ann. Surg. Oncol., April 1, 2004; 11(4): 387 - 392. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Deraco, D. Baratti, M. G. Inglese, B. Allaria, S. Andreola, C. Gavazzi, and S. Kusamura Peritonectomy and Intraperitoneal Hyperthermic Perfusion (IPHP): A Strategy That Has Confirmed its Efficacy in Patients with Pseudomyxoma Peritonei Ann. Surg. Oncol., April 1, 2004; 11(4): 393 - 398. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Shen, J. Hawksworth, J. Lovato, B. W. Loggie, K. R. Geisinger, R. A. Fleming, and E. A. Levine Cytoreductive Surgery and Intraperitoneal Hyperthermic Chemotherapy With Mitomycin C for Peritoneal Carcinomatosis from Nonappendiceal Colorectal Carcinoma Ann. Surg. Oncol., February 1, 2004; 11(2): 178 - 186. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. J. Verwaal, S. van Ruth, E. de Bree, G. W. van Slooten, H. van Tinteren, H. Boot, and F. A.N. Zoetmulder Randomized Trial of Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy Versus Systemic Chemotherapy and Palliative Surgery in Patients With Peritoneal Carcinomatosis of Colorectal Cancer J. Clin. Oncol., October 15, 2003; 21(20): 3737 - 3743. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. H. Sugarbaker Clinical Research to Standard of Care: When Does the Transition Occur? Ann. Surg. Oncol., October 1, 2003; 10(8): 825 - 826. [Full Text] [PDF]
|
|
|
|
|
|
O. A. Stuart, L. S. Welch, and P. H. Sugarbaker Operating Room Environmental Safety With Heated Intraperitoneal Chemotherapy Ann. Surg. Oncol., August 1, 2003; 10(7): 822 - 823. [Full Text] [PDF]
|
|
|
|
 |
|
 P. Shen, E. A. Levine, J. Hall, D. Case, G. Russell, R. Fleming, R. McQuellon, K. R. Geisinger, and B. W. Loggie Factors Predicting Survival After Intraperitoneal Hyperthermic Chemotherapy With Mitomycin C After Cytoreductive Surgery for Patients With Peritoneal Carcinomatosis Arch Surg, January 1, 2003; 138(1): 26 - 33. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. H. Sugarbaker Review of a Personal Experience in the Management of Carcinomatosis and Sarcomatosis Jpn. J. Clin. Oncol., December 1, 2001; 31(12): 573 - 583. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
